CN101165049A - 含磺酰胺的吲哚化合物结晶 - Google Patents

含磺酰胺的吲哚化合物结晶 Download PDF

Info

Publication number
CN101165049A
CN101165049A CNA2007101667949A CN200710166794A CN101165049A CN 101165049 A CN101165049 A CN 101165049A CN A2007101667949 A CNA2007101667949 A CN A2007101667949A CN 200710166794 A CN200710166794 A CN 200710166794A CN 101165049 A CN101165049 A CN 101165049A
Authority
CN
China
Prior art keywords
crystallization
cyano group
peak
crystalline substance
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101667949A
Other languages
English (en)
Chinese (zh)
Inventor
高桥恵子
林宪司
阿部太一
大前贵生
加藤隆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN101165049A publication Critical patent/CN101165049A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CNA2007101667949A 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶 Pending CN101165049A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003318953 2003-09-10
JP318953/2003 2003-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800260696A Division CN100406440C (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶及其制造方法

Publications (1)

Publication Number Publication Date
CN101165049A true CN101165049A (zh) 2008-04-23

Family

ID=34308544

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007101667949A Pending CN101165049A (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶
CNB2004800260696A Expired - Fee Related CN100406440C (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶及其制造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004800260696A Expired - Fee Related CN100406440C (zh) 2003-09-10 2004-09-01 含磺酰胺的吲哚化合物结晶及其制造方法

Country Status (24)

Country Link
US (2) US7754894B2 (enExample)
EP (1) EP1666463B1 (enExample)
JP (1) JP4435090B2 (enExample)
KR (1) KR20060120644A (enExample)
CN (2) CN101165049A (enExample)
AT (1) ATE486849T1 (enExample)
AU (1) AU2004272400B2 (enExample)
BR (1) BRPI0414314A (enExample)
CA (1) CA2536995C (enExample)
CY (1) CY1110975T1 (enExample)
DE (1) DE602004029907D1 (enExample)
DK (1) DK1666463T3 (enExample)
ES (1) ES2354286T3 (enExample)
HR (1) HRP20100631T1 (enExample)
IL (2) IL174059A0 (enExample)
MX (1) MXPA06002732A (enExample)
NO (1) NO335256B1 (enExample)
NZ (1) NZ546111A (enExample)
PL (1) PL1666463T3 (enExample)
PT (1) PT1666463E (enExample)
RU (1) RU2336269C2 (enExample)
SI (1) SI1666463T1 (enExample)
TW (1) TW200514770A (enExample)
WO (1) WO2005026118A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3868534B2 (ja) * 1996-05-24 2007-01-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド誘導体の製造法および中間体
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
ES2341843T3 (es) * 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2005026118A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の結晶およびその製造方法

Also Published As

Publication number Publication date
WO2005026118A1 (ja) 2005-03-24
CN100406440C (zh) 2008-07-30
DK1666463T3 (da) 2010-12-20
TWI349663B (enExample) 2011-10-01
CY1110975T1 (el) 2015-06-11
NO20061545L (no) 2006-06-09
EP1666463B1 (en) 2010-11-03
HRP20100631T1 (hr) 2010-12-31
CA2536995C (en) 2013-12-17
EP1666463A1 (en) 2006-06-07
TW200514770A (en) 2005-05-01
KR20060120644A (ko) 2006-11-27
AU2004272400A1 (en) 2005-03-24
ATE486849T1 (de) 2010-11-15
PL1666463T3 (pl) 2011-04-29
BRPI0414314A (pt) 2006-10-31
NO335256B1 (no) 2014-10-27
RU2006111454A (ru) 2006-08-27
JPWO2005026118A1 (ja) 2007-11-08
DE602004029907D1 (de) 2010-12-16
PT1666463E (pt) 2011-01-17
IL174059A0 (en) 2006-08-01
US7754894B2 (en) 2010-07-13
US20090247768A1 (en) 2009-10-01
AU2004272400B2 (en) 2010-03-04
US20070082941A1 (en) 2007-04-12
CN1849305A (zh) 2006-10-18
IL196569A0 (en) 2011-07-31
EP1666463A4 (en) 2007-12-12
HK1092796A1 (en) 2007-02-16
MXPA06002732A (es) 2006-06-05
CA2536995A1 (en) 2005-03-24
NZ546111A (en) 2008-11-28
JP4435090B2 (ja) 2010-03-17
SI1666463T1 (sl) 2011-02-28
ES2354286T3 (es) 2011-03-11
RU2336269C2 (ru) 2008-10-20

Similar Documents

Publication Publication Date Title
ES2772498T3 (es) Preparación de un inhibidor mek y formulación que comprende el mismo
JP7047772B2 (ja) Ｂｒｋ阻害化合物
JP2019528318A (ja) 血液脳関門通過能を有する置換キナゾリン化合物
CN104557871B (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
EP3805229B1 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
JP2002506864A (ja) 細胞増殖の阻害のための置換ビスインドリルマレイミド類
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN100406440C (zh) 含磺酰胺的吲哚化合物结晶及其制造方法
KR101065984B1 (ko) 테모졸로마이드 에스테르를 포함하는 약학 조성물
CN101103025B (zh) 5-[2-氨基-4-(2-呋喃基)嘧啶-5-基]-1-甲基吡啶-2(1h)-酮的结晶及其制备方法
KR20080007649A (ko) 피페리딘환을 가지는 인돌 유도체의 결정 및 그의 제조방법
EP3088402A1 (en) CRYSTALS (2) OF PYRAZINO[2,1-c][1,2,4]TRIAZINE COMPOUND
JP2018002644A (ja) （Ｓ）−Ｎ−（４−アミノ−５−（キノリン−３−イル）−６，７，８，９−テトラヒドロピリミド［５，４−ｂ］インドリジン−８−イル）アクリルアミドの結晶
JP2006527235A (ja) １，３，４−トリアザフェナレンおよび１，３，４，６−テトラアザフェナレン誘導体
JP7169695B2 (ja) ピラジノ［２，１－ｃ］［１，２，４］トリアジン化合物の結晶（１）
HK1092796B (en) Crystal of sulfonamide-containing indole compound and process for producing the same
CN101175751B (zh) 具有哌啶环的吲哚衍生物的晶体和其制备方法
HK40052813A (en) Pyridine salts and process
HK40040064B (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
HK40040064A (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
HK40005148B (en) Pyridine compound
HK40005148A (en) Pyridine compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20080423

C20 Patent right or utility model deemed to be abandoned or is abandoned